Skip to main content

Or 34,00 After 66% tax deduction

I make a monthly donation I make an IFI donation
Imagerie cérébrale Corti Corvol Parkinson

What are the treatments for Parkinson's disease?

Last update: 12/10/2024 Reading time: 1min

The therapeutic management of Parkinson's disease is multidisciplinary. The drug treatments used are aimed at restoring synaptic transmission between dopaminergic neurons.

Treatments

Treatments for Parkinson's Disease

L-DOPA is a precursor that can cross the blood-brain barrier, the cellular barrier responsible for protecting the brain.

Dopamine agonists are molecules that have the same effect as dopamine. They can also be delivered subcutaneously (apomorphine pump), which allows for more regular and continuous treatment and better balance the patient. It is then a treatment in forms of longer duration of evolution (“second-line treatment”).

These treatments for Parkinson’s disease improve patients’ quality of life and delay the disease’s motor progression. However, they result in adverse reactions that are more or less intense and frequent, depending on the patient.
 

Drug treatments

Drug treatments, side effects

These side effects may include nausea, vomiting, low blood pressure, drowsiness, hallucinations or an abnormal perception of reality, compulsive use of medications, all of which should lead you to consult your general practitioner.

The best known of these side effects are impulse control disorders, observed in 20% of patients under dopaminergic agonists. These disorders take the form of an addiction to gambling, shopping, eating disorders, hypersexuality or risky behaviour, for example.

Some of these disorders are reversible by decreasing treatment doses but may require complete discontinuation of medication.
 

At Paris Brain Institute

At Paris Brain Institute

A study coordinated by Professor Jean-Christophe CORVOL, Director of the Centre for Clinical Investigation and Team Leader at Paris Brain Institute involved a cohort of 400 patients recruited throughout France through the French network for clinical research on Parkinson’s disease (NS-PARK/FCRIN). Patients were followed for 5 years to assess symptoms, readapt treatments, and identify the development of behavioural problems. This study shows that the onset of behavioural disorders increases with the duration of parkinson’s disease. Inclusively, 20% of patients had these disorders compared to 33% after 5 years. Of the patients without disorders at the beginning of the study, almost 50% developed them during the 5 years of follow-up.

These findings indicate that regular monitoring of patients under Parkinson's therapy is essential. With this in mind, the AD SCIENTIAM start-up incubated at Paris Brain Institute makes it possible to study the fluctuations of the symptoms of the disease on a daily basis in the patient’s home in real life. This device is currently being tested on the NS-PARK cohort and is intended to facilitate the introduction of therapies adapted by neurologists.
 

Treatment of various disorders

Treatment of various disorders of parkinson's disease

Late-onset walking disorders can be treated by HealthTrends Stimulations. In this therapy an electrode is implanted in the target brain region most often in the subthalamic nucleus or internal pallidum. This implantation is very often done under local anaesthesia in order to adjust the location of the electrode for an optimal reduction of symptoms. The implanted electrode acts by the same mechanism as a pace maker, delivering electrical pulses at high frequencies regularly. For example, stimulation of the thalamus reduced resting tremor in 80% of cases.

Stimulation in the internal pallidum reduces involuntary abnormal movements in an average of 60% of patients. Subhalamic nucleus stimulation resulted in a 60% decrease in motor symptoms characteristic of parkinsonian syndrome.
 

At Paris Brain Institute

At Paris Brain Institute

The team of Dr. Carine KARACHI and Brian LAU at Paris Brain Institute is studying the anatomy of the subcortical region with the ultimate goal of developing new therapies and applications for deep brain stimulation.

The Brain e-NOVATION joint laboratory at Paris Brain Institute has developed a therapeutic game “Toap Run” aimed at improving balance and walking disorders of Parkinson’s patients. In this interactive game, the patient must perform movements that concern the whole body and the axial motor in particular, with lateral movements, movements of the trunk in order to collect as many pieces as possible while avoiding obstacles.
 

27.11.2019 Dr Carine KARACHI parle de la stimulation cérébrale profonde

Our news on the subject

Réprésentation du danse lors du petit déjeuner
2023 Art-Science Breakfast: restoring movement for Parkinson’s patients
In partnership with the Paris+ par Art Basel contemporary art fair, the 12th edition of the Art-Science Breakfast took place on October 18, 2023 at Café de l’Homme. Thanks to support from the NRJ Foundation at Institut de France and the incredible ...
10.20.2023 Support
image
How to discern impulsivity from alteration of anticipation?
In everyday life, we all need to anticipate our actions. On the road, for example, we need to start or cross when the light turns green. While the light is red, our brain prepares to act as quickly as possible as soon as the color changes because we ...
10.13.2022 Research, science & health
image
Genetics of early-onset parkinsonism with intellectual disability
A research team from the Paris Brain Institute (Inserm/CNRS/Sorbonne University/AP-HP) just identified mutations in familial cases with early-onset Parkinsonism and intellectual disability. Genetic studies on two affected siblings pairs highlighted ...
09.29.2022 Research, science & health
Un chercheur
World Parkinson's Day 2022: where does research stand?
On the occasion of World Parkinson's Day, which will be held on 11 April 2022, the Paris Brain Institute takes stock of the latest advances in research and the challenges that remain in the fight against the second most common neurodegenerative ...
04.11.2022 Research, science & health
image
Artificial Intelligence-based MRI biomarker of Isolated REM Sleep Behavior Disorder and Parkinson's disease
Rahul Gaurav, a research Engineer in the MOV’IT team led by Pr. Stéphane Lehéricy and Pr. Marie Vidailhet, at the Paris Brain Institute, developed an artificial intelligence framework to investigate fully automatic neurodegeneration in the substantia ...
02.18.2022 Research, science & health
sommeil
Sleepwalking and behavioral disorders in rem sleep: shared characteristics?
Restlessness in sleep is common, however it may be a symptom of two illnesses that seem to be complete opposites: sleepwalking and behavioral disorders in REM sleep. The first affects a younger population and takes place during deep sleep, whereas ...
07.26.2017 Research, science & health
See all our news